Effect of Everolimus with Low-Dose Tacrolimus on Development of New-Onset Diabetes After Transplantation and Allograft Function in Kidney Transplantation: A Multicenter, Open-Label, Randomized Trial

22 January 2021: Original Paper

Hyung Duk Kim ^1BEF , Ji-Yeun Chang ^1CDE , Byung Ha Chung ^1AB , Chan-Duck Kim ^2B , Sang-Ho Lee ^3B , Yeong Hoon Kim ^4B , Chul Woo Yang ^1ADG*

DOI: 10.12659/AOT.927984

Ann Transplant 2021; 26:e927984

Table 4 Comparison of the allograft function.

	EVL group	TAC group	P-value*
ITT population	N=38	N=39

Baseline	61.39±13.32	62.98±12.46	0.6209
12 months	63.12±14.36	66.56±16.04	0.6103
Mean change from baseline	1.73±10.61	3.58±13.46	0.8905
p-value^**	0.3216	0.1878

Baseline	225.47±688.86	172.98±307.80	0.3633
12 months	584.04±2087.43	141.75±245.63	0.4789
Mean change from baseline	358.58±1814.96	−28.47±241.46	0.0035
p-value^**		0.4399

Baseline	0 (0.00)	0 (0.00)	NA
12 months	1 (0.38)	0 (0.00)	0.4935
	1 (2.63)	0 (0.00)	0.3110
	0 (0.00)	0 (0.00)	NA


Baseline	60.84±12.84	62.85±12.60	0.5667
12 months	64.90±13.02	66.89±16.12	0.9416
Mean change from baseline	4.06±10.22	4.04±13.32	0.5802
p-value^**	0.0491	0.1094

Baseline	145.56±297.15	176.46±311.28	0.5589
12 months	649.40±2371.10	144.32±248.39	0.1898
Mean change from baseline	503.84±2147.56	−29.23±244.74	0.0016
p-value^**		0.4691

Baseline	0 (0.00)	0 (0.00)	NA
12 months	1 (3.70)	0 (0.00)	0.4242
^* Wilcoxon’s rank sum test; ^** Wilcoxon’s signed rank test. BPAR – biopsy-proven acute rejection, cumulative rate for 12 months. Allograft loss, cumulative rate for 12 months. Discrete variables are presented with n (%), and continuous variables with normal distributions are presented with mean±S.D. ACR – albumin-to creatinine ratio.